curasafehealthcare.com
  • Home
  • About
  • Services
  • Therapeutic Areas
  • Careers
  • Latest News
  • Contact Us
Select Page

Research on the Improvement of Intestinal and Immune Functions by Probiotics

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​ Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo Sponsors: Wecare Probiotics Co., Ltd. Not yet recruiting Conditions: Intestinal Health Interventions: Dietary Supplement: Probiotic; Dietary Supplement: Placebo...
Expert Explores Trials in CIS-Refractory Bladder Cancer

Expert Explores Trials in CIS-Refractory Bladder Cancer

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder cancer space and data from several clinical trials evaluating agents for bladder cancer.  Jason M. Hafron, MD, CMO, discusses recent approvals in the non–muscle-invasive bladder...
Advarra Unveils Oncology Research Pulse

Advarra Unveils Oncology Research Pulse

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical research technology, today announced the launch of Oncology Research…  /PRNewswire/ — Advarra, the market leader in regulatory review solutions and clinical...
QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

QurAlis Announces Topline Data From its Phase 1 Clinical Trial of QRL-101 Evaluating Biomarkers of ALS and Epilepsy in Healthy Volunteers

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  /PRNewswire/ — QurAlis Corporation (“QurAlis”), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that…  /PRNewswire/ — QurAlis Corporation (“QurAlis”), a...
Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals

Gilead Sciences’ annual HIV prevention injection shows promise in clinical trial, Lancet study reveals

by palligoelme@gmail.com | Mar 12, 2025 | Clinical Trials

​  The drug, which works by blocking HIV from entering and multiplying in human cells, remained in the body for at least 56 weeks, according to the phase 1 randomised controlled trial.  The drug, which works by blocking HIV from entering and multiplying in human...
« Older Entries
Next Entries »

Recent Posts

  • School Nurse-Led Help-Seeking Program in Middle School Students
  • Safety and Efficacy of EUS-RFA in Pancreatic Insulinoma
  • AI-Based Multimodal Integration for Tumor Microenvironment Analysis and Response Prediction in HCC Treated With TACE Plus Immunotherapy and Targeted Therapy (CHANCE2601)
  • Measuring Reliability of Spine Mobilization in Low Back Pain
  • Biceps Femoris Short Head (BiFeS) Block and Adductor Canal Block for Postoperative Analgesia Following Total Knee Arthroplasty

Recent Comments

No comments to show.

Curasafe healthcare solutions Pvt. Ltd. provides comprehensive services including safety program oversight, risk management, and regulatory compliance.

Important Links

  • Home
  • Contact Us
Connect With Us

Contact


711, Shivalik Satyamev, Bopal Ambli Junction, Bopal, Ahmedabad, Daskroi, Gujarat, India, 380058.


info@curasafehealthcare.com



(+91) 97803 81065

Copyright © 2025 Curasafehealthcare ®